CoChat
Sign Up
Cited by 91Glioma Diagnosis and TreatmentNanoparticle-Based Drug DeliveryBarrier Structure and Function Studies

Delivery of Local Therapeutics to the brain: Working Toward Advancing Treatment for Malignant Gliomas

Open access
Chaichana, Kaisorn L, Pinheiro, Leon, Brem, Henry·2015·Therapeutic Delivery
DOI 10.4155/tde.14.114PMC PMC4696051
Open this paper in CoChat — free account

Abstract

Malignant gliomas, including glioblastoma and anaplastic astrocytomas, are characterized by their propensity to invade surrounding brain parenchyma, making curative resection difficult. These tumors typically recur within two centimeters of the resection cavity even after gross total removal. As a result, there has been an emphasis on developing therapeutics aimed at achieving local disease control. In this review, we will summarize the current developments in the delivery of local therapeutics, namely direct injection, convection-enhanced delivery and implantation of drug-loaded polymers, as well as the application of these therapeutics in future methods including microchip drug delivery and local gene therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/tde.14.114

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An intracerebral injection avoids the tissue barrier that the blood-CSF barrier or blood-brain-barrier represents and consequently should lead to significantly higher brain transfection levels by specifically targeting local regions of the brain.

    “An intracerebral injection avoids the tissue barrier that blood-cerebrospinal fluid (CSF) barrier or blood-brain-barrier (BBB) represents, and consequently should lead to significantly higher brain transfection levels by specifically targeting local regions of the brain (4, 20, 22, 26, 27).”

    From Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection (2023) · cites this paper as [20]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • Intracerebral injections are clinically feasible and are performed in a variety of clinical scenarios and preclinical settings.

    “Intracerebral injections are clinically feasible, and are performed in a variety of clinical scenarios (17–23), as well as in various preclinical settings (4, 24–27).”

    From Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection (2023) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 121

  1. [1]Dubrow R Darefsky AS Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007 BMC Cancer 11 325 2011 21801393 PMC3163630
  2. [2]Tait MJ Petrik V Loosemore A Bell BA Papadopoulos MC Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases Br J Neurosurg 21 5 496 500 2007 17852105
  3. [3]Chaichana K Zamora-Berridi G Camara-Quintana J Quinones-Hinojosa A Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies Stem Cells 24 12 2851 2857 2006 16945995
  4. [4]Chaichana KL Capilla-Gonzalez V Gonzalez-Perez O Preservation of glial cytoarchitecture from ex vivo human tumor and non-tumor cerebral cortical explants: a human model to study neurological diseases J Neurosci Methods 164 2 261 270 2007 17580092 PMC2744592
  5. [5]Chaichana KL Guerrero-Cazares H Capilla-Gonzalez V Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells J Neurosci Methods 180 1 116 125 2009 19427538 PMC2696820
  6. [6]Quinones-Hinojosa A Chaichana K The human subventricular zone: a source of new cells and a potential source of brain tumors Exp Neurol 205 2 313 324 2007 17459377
  7. [7]De Bock M Vandenbroucke RE Decrock E Culot M Cecchelli R Leybaert L A new angle on blood-CNS interfaces: a role for connexins? FEBS Lett 588 8 1259 1270 2014 24631535
  8. [8]Lesniak MS Brem H Targeted therapy for brain tumours Nat Rev Drug Discov 3 6 499 508 2004 15173839
  9. Raza SM Pradilla G Legnani FG Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours Expert Opin Biol Ther 5 4 477 494 2005 Details the history of controlled-release polymers for the treatment of malignant astrocytomas 15934827
  10. [10]Voges J Reszka R Gossmann A Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma Ann Neurol 54 4 479 487 2003 14520660
  11. [11]Walter KA Tamargo RJ Olivi A Burger PC Brem H Intratumoral chemotherapy Neurosurgery 37 6 1128 1145 1995 8584154
  12. [12]Farra R Sheppard NF Jr McCabe L First-in-human testing of a wirelessly controlled drug delivery microchip Sci Transl Med 4 122 122ra21 2012 22344516
  13. [13]Scott AW Tyler BM Masi BC Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model Biomaterials 32 10 2532 2539 2011 21220172
  14. Chaichana K Parker S Olivi A Quinones-Hinojosa A A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme J Neurosurg 112 5 997 1004 2010 Assigns preoperative risk of survival for patients with glioblastoma 19817542
  15. [15]Chaichana KL Cabrera-Aldana EE Jusue-Torres I When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg 82 1–2 e257 e265 2014 24508595
  16. [16]Chaichana KL Chaichana KK Olivi A Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article J Neurosurg 114 3 587 594 2011 20887095 PMC4020429
  17. [17]Chaichana KL Garzon-Muvdi T Parker S Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients Ann Surg Oncol 18 1 239 245 2011 20697823 PMC4612568
  18. [18]Chaichana KL McGirt MJ Frazier J Attenello F Guerrero-Cazares H Quinones-Hinojosa A Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection J Neurooncol 89 2 219 224 2008 18458819
  19. [19]Chaichana KL Parker SL Mukherjee D Cheng JS Gokaslan ZL McGirt MJ Assessment of the extent of surgical resection as a predictor of survival in patients with primary osseous spinal neoplasms Clin Neurosurg 58 117 121 2011 21916135
  20. [20]Lacroix M Abi-Said D Fourney DR A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 2 190 198 2001 11780887
  21. [21]Lamborn KR Chang SM Prados MD Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis Neuro Oncol 6 3 227 235 2004 15279715 PMC1871999
  22. [22]Laws ER Parney IF Huang W Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project J Neurosurg 99 3 467 473 2003 12959431
  23. McGirt MJ Chaichana KL Gathinji M Independent association of extent of resection with survival in patients with malignant brain astrocytoma J Neurosurg 110 1 156 162 2009 Study identifies the role of extent of resection with survival for patients with malignant gliomas 18847342
  24. McGirt MJ Mukherjee D Chaichana KL Than KD Weingart JD Quinones-Hinojosa A Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme Neurosurgery 65 3 463 469 discussion 469–470 2009 Identifies the importance of surgical resection while avoiding iatrogenic deficits 19687690
  25. [25]Stupp R Mason WP van den Bent MJ Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 987 996 2005 15758009
  26. [26]Chaichana KL Zadnik P Weingart JD Multiple resections for patients with glioblastoma: prolonging survival J Neurosurg 118 4 812 820 2013 23082884 PMC3700339
  27. Chaichana KL Jusue-Torres I Navarro-Ramirez R Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma Neuro Oncol 16 1 113 122 2014 Established minimum percent resection thresholds and maximum residual volume thresholds associated with survival for patients with glioblastoma 24285550 PMC3870832
  28. [28]Chaichana KL Kosztowski T Niranjan A Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults J Neurosurg 113 2 286 292 2010 20302391
  29. [29]Sathornsumetee S Rich JN New treatment strategies for malignant gliomas Expert Rev Anticancer Ther 6 7 1087 1104 2006 16831080
  30. Brem H Piantadosi S Burger PC Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group Lancet 345 8956 1008 1012 1995 The first randomized-control trial to establish the efficacy of drug-impregnanted polymers for recurrent glioblastoma 7723496
  31. [31]Chaichana KL Halthore AN Parker SL Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article J Neurosurg 114 3 604 612 2011 20524825 PMC3725949
  32. [32]Chaichana KL Zaidi H Pendleton C The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival Neurol Res 33 7 759 764 2011 21756557 PMC4612577
  33. [33]Chang CH Horton J Schoenfeld D Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study Cancer 52 6 997 1007 1983 6349785
  34. [34]Chang SM Parney IF McDermott M Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project J Neurosurg 98 6 1175 1181 2003 12816260
  35. [35]McGirt MJ Than KD Weingart JD Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 3 583 588 2009 19046047 PMC4856017
  36. [36]Sanai N Polley MY McDermott MW Parsa AT Berger MS An extent of resection threshold for newly diagnosed glioblastomas J Neurosurg 115 1 3 8 2011 21417701
  37. [37]Chaichana KL Pendleton C Chambless L Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma J Clin Neurosci 20 10 1422 1426 2013 23928040 PMC4086640
  38. [38]Hegi ME Diserens AC Gorlia T MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 997 1003 2005 15758010
  39. [39]Parsons DW Jones S Zhang X An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 1807 1812 2008 18772396 PMC2820389
  40. [40]Walker MD Alexander E Jr Hunt WE Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial J Neurosurg 49 3 333 343 1978 355604
  41. [41]Hochberg FH Pruitt A Assumptions in the radiotherapy of glioblastoma Neurology 30 9 907 911 1980 6252514
  42. [42]Brem H Ewend MG Piantadosi S Greenhoot J Burger PC Sisti M The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial J Neurooncol 26 2 111 123 1995 8787853
  43. [43]Valtonen S Timonen U Toivanen P Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 1 44 48 discussion 48–49 1997 9218294
  44. Westphal M Hilt DC Bortey E A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 5 2 79 88 2003 Established the importance of drug-impregnated polymers for primary glioblastoma 12672279 PMC1920672
  45. [45]Westphal M Ram Z Riddle V Hilt D Bortey E Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 3 269 275 discussion 275 2006 16482400
  46. [46]Gallia GL Brem S Brem H Local treatment of malignant brain tumors using implantable chemotherapeutic polymers J Natl Compr Canc Netw 3 5 721 728 2005 16194460
  47. [48]Metcalfe SE Grant R Biopsy versus resection for malignant glioma Cochrane Database Syst Rev 3 CD002034 2001 11687008
  48. [49]Andersen AP Postoperative irradiation of glioblastomas. Results in a randomized series Acta Radiol Oncol Radiat Phys Biol 17 6 475 484 1978 216238
  49. [50]Bleehen NM Stenning SP A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party Br J Cancer 64 4 769 774 1991 1654987 PMC1977696
  50. [51]Garden AS Maor MH Yung WK Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas Radiother Oncol 20 2 99 110 1991 1851573
  51. [52]Molenaar RJ Verbaan D Lamba S The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone Neuro Oncol 16 9 1263 73 2014 24510240 PMC4136888
  52. [53]Esteller M Garcia-Foncillas J Andion E Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 19 1350 1354 2000 11070098
  53. [54]Groothuis DR Fischer JM Lapin G Bigner DD Vick NA Permeability of different experimental brain tumor models to horseradish peroxidase J Neuropathol Exp Neurol 41 2 164 185 1982 7062086
  54. [55]Neuwelt EA Barnett PA Bigner DD Frenkel EP Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier Proc Natl Acad Sci USA 79 14 4420 4423 1982 6289301 PMC346683
  55. [56]Liu HL Fan CH Ting CY Yeh CK Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview Theranostics 4 4 432 444 2014 24578726 PMC3936295
  56. [57]Riva P Franceschi G Frattarelli M 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma–phase I and II study Acta Oncol 38 3 351 359 1999 10380827
  57. [58]Gaspar LE Zamorano LJ Shamsa F Fontanesi J Ezzell GE Yakar DA Permanent 125iodine implants for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 43 5 977 982 1999 10192343
  58. [59]Torres LA Coca MA Batista JF Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas Nucl Med Commun 29 1 66 75 2008 18049099
  59. [60]Bartolomei M Mazzetta C Handkiewicz-Junak D Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide Q J Nucl Med Mol Imaging 48 3 220 228 2004 15499296
  60. [61]Paganelli G Bartolomei M Ferrari M Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results Cancer Biother Radiopharm 16 3 227 235 2001 11471487
  61. [62]Prados MD McDermott M Chang SM Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial J Neurooncol 65 3 269 278 2003 14682377
  62. [63]Goetz C Riva P Poepperl G Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times J Neurooncol 62 3 321 328 2003 12777085
  63. [64]Jung G Brandl M Eisner W Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy Int J Cancer 91 2 225 230 2001 11146449
  64. [65]Quattrocchi KB Miller CH Cush S Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas J Neurooncol 45 2 141 157 1999 10778730
  65. [66]Bigner DD Brown MT Friedman AH Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results J Clin Oncol 16 6 2202 2212 1998 9626222
  66. [67]Patchell RA Regine WF Ashton P A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme J Neurooncol 60 1 37 42 2002 12416544
  67. [68]Boiardi A Eoli M Salmaggi A New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM) J Exp Clin Cancer Res 22 4 Suppl 123 127 2003 16767918
  68. [69]Lang FF Bruner JM Fuller GN Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results J Clin Oncol 21 13 2508 2518 2003 12839017
  69. [70]Ferroli P Broggi M Franzini A Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note Neurosurgery 59 2 E433 E434 discussion E433–E434 2006 16883158
  70. [71]Boiardi A Silvani A Eoli M Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? J Neurooncol 88 1 105 113 2008 18283418
  71. [72]Voulgaris S Partheni M Karamouzis M Dimopoulos P Papadakis N Kalofonos HP Intratumoral doxorubicin in patients with malignant brain gliomas Am J Clin Oncol 25 1 60 64 2002 11823699
  72. [73]Boiardi A Eoli M Salmaggi A Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours J Neurooncol 54 1 39 47 2001 11763421
  73. [74]Boiardi A Silvani A Pozzi A Fariselli L Broggi G Salmaggi A Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies J Neurooncol 41 2 151 157 1999 10222435
  74. [75]Boiardi A Eoli M Pozzi A Salmaggi A Broggi G Silvani A Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients Ital J Neurol Sci 20 1 43 48 1999 10933484
  75. [76]Oshiro S Tsugu H Komatsu F Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma Anticancer Res 26 6A 4027 4032 2006 17195453
  76. [77]Koch D Hundsberger T Boor S Kaina B Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma J Neurooncol 82 1 85 89 2007 17031555
  77. [78]Nakagawa K Kamezaki T Shibata Y Tsunoda T Meguro K Nose T Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors Neurol Med Chir (Tokyo) 35 1 22 27 1995 7700478
  78. [79]Hadaczek P Mirek H Berger MS Bankiewicz K Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors J Neurosurg 102 2 328 335 2005 15739562
  79. [80]Boiardi A Salmaggi A Pozzi A Broggi G Silvani A Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data J Neurooncol 27 2 157 162 1996 8699238
  80. [81]Bobo RH Laske DW Akbasak A Morrison PF Dedrick RL Oldfield EH Convection-enhanced delivery of macromolecules in the brain Proc Natl Acad Sci USA 91 6 2076 2080 1994 8134351 PMC43312
  81. [82]Lieberman DM Laske DW Morrison PF Bankiewicz KS Oldfield EH Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion J Neurosurg 82 6 1021 1029 1995 7539062
  82. [83]Kunwar S Prados MD Chang SM Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 7 837 844 2007 17327604
  83. [84]Sampson JH Akabani G Friedman AH Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies Neurosurg Focus 20 4 E14 2006 16709019
  84. [85]Tanner PG Holtmannspotter M Tonn JC Goldbrunner R Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note Neurosurgery 61 4 E880 E882 discussion E882 2007 17986926
  85. [86]Varenika V Dickinson P Bringas J Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery J Neurosurg 109 5 874 880 2008 18976077 PMC2725182
  86. [87]Bruce JN Fine RL Canoll P Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan Neurosurgery 69 6 1272 1279 discussion 1279–1280 2011 21562434 PMC4940854
  87. [88]Saito R Sonoda Y Kumabe T Nagamatsu K Watanabe M Tominaga T Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride J Neurosurg Pediatr 7 5 522 526 2011 21529193
  88. [89]Lidar Z Mardor Y Jonas T Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study J Neurosurg 100 3 472 479 2004 15035283
  89. [90]Carpentier A Metellus P Ursu R Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study Neuro Oncol 12 4 401 408 2010 20308317 PMC2940609
  90. [91]Patel SJ Shapiro WR Laske DW Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients Neurosurgery 56 6 1243 1252 discussion 1252–1253 2005 15918940
  91. [92]Bogdahn U Hau P Stockhammer G Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro Oncol 13 1 132 142 2011 20980335 PMC3018908
  92. [93]Kunwar S Chang S Westphal M Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma Neuro Oncol 12 8 871 881 2010 20511192 PMC2940677
  93. [94]Boiardi A Eoli M Salmaggi A Local drug delivery in recurrent malignant gliomas Neurol Sci 26 Suppl 1 S37 S39 2005 15883691
  94. [95]Sampson JH Akabani G Archer GE Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors J Neurooncol 65 1 27 35 2003 14649883
  95. [96]Brem H Mahaley MS Jr Vick NA Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas J Neurosurg 74 3 441 446 1991 1993909
  96. [97]Brem H Piantadosi S Burger PC Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 345 8956 1008 1012 1995 7723496
  97. [98]Olivi A Ewend MG Utsuki T Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat Cancer Chemother Pharmacol 39 1–2 90 96 1996 8995504
  98. [99]Menei P Capelle L Guyotat J Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial Neurosurgery 56 2 242 248 discussion 242–248 2005 15670372
  99. [100]Gref R Minamitake Y Peracchia MT Trubetskoy V Torchilin V Langer R Biodegradable long-circulating polymeric nanospheres Science 263 5153 1600 1603 1994 8128245
  100. [101]Gabizon A Isacson R Libson E Clinical studies of liposome-encapsulated doxorubicin Acta Oncol 33 7 779 786 1994 7993646
  101. [102]Rhines LD Sampath P DiMeco F Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma Neurosurgery 52 4 872 879 discussion 879–880 2003 12657184
  102. Olivi A Grossman SA Tatter S Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial J Clin Oncol 21 9 1845 1849 2003 Established that higher percentage of drug could safely be used in drug-impregnated polymers 12721262
  103. [104]Fung LK Ewend MG Sills A Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain Cancer Res 58 4 672 684 1998 9485020
  104. [105]Menei P Metellus P Parot-Schinkel E Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience Ann Surg Oncol 17 7 1740 1746 2010 20443147
  105. [106]Hart MG Grant R Garside R Rogers G Somerville M Stein K Chemotherapy wafers for high grade glioma Cochrane Database Syst Rev 3 CD007294 2011 21412902 PMC6457755
  106. [107]Aoki T Nishikawa R Sugiyama K A multicenter phase I/II study of the BCNU implant (Gliadel((R)) wafer) for Japanese patients with malignant gliomas Neurol Med Chir (Tokyo) 54 4 290 301 2014 24739422 PMC4533485
  107. [108]McGirt MJ Brem H Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy Ann Surg Oncol 17 7 1729 1731 2010 20422453
  108. [109]Noel G Schott R Froelich S Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas Int J Radiat Oncol Biol Phys 82 2 749 755 2012 21300471
  109. [110]Miglierini P Bouchekoua M Rousseau B Hieu PD Malhaire JP Pradier O Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity Clin Neurol Neurosurg 114 9 1222 1225 2012 22464950
  110. [111]Pan E Mitchell SB Tsai JS A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients J Neurooncol 88 3 353 357 2008 18389176
  111. [112]Salvati M D’Elia A Frati A Brogna C Santoro A Delfini R Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis J Neurosurg Sci 55 1 1 6 2011 21464805
  112. [113]Lechapt-Zalcman E Levallet G Dugue AE O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide Cancer 118 18 4545 4554 2012 22359215
  113. [114]Gururangan S Cokgor L Rich JN Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro Oncol 3 4 246 250 2001 11584894 PMC1920622
  114. [115]Salmaggi A Milanesi I Silvani A Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results J Neurosurg 118 4 821 829 2013 23350777
  115. [116]McPherson CM Gerena-Lewis M Breneman JC Warnick RE Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy J Neurooncol 108 3 521 525 2012 22467191
  116. [117]Quinn JA Jiang SX Carter J Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme Clin Cancer Res 15 3 1064 1068 2009 19188181 PMC2710963
  117. [119]Santini JT Jr Cima MJ Langer R A controlled-release microchip Nature 397 6717 335 338 1999 9988626
  118. [120]Tyler MA Sonabend AM Ulasov IV Lesniak MS Vector therapies for malignant glioma: shifting the clinical paradigm Expert Opin Drug Deliv 5 4 445 458 2008 18426385
  119. [121]Tzeng SY Guerrero-Cazares H Martinez EE Sunshine JC Quinones-Hinojosa A Green JJ Non-viral gene delivery nanoparticles based on poly(beta-amino esters) for treatment of glioblastoma Biomaterials 32 23 5402 5410 2011 21536325 PMC3118545
  120. [122]Wirth T Samaranayake H Pikkarainen J Maatta AM Yla-Herttuala S Clinical trials for glioblastoma multiforme using adenoviral vectors Curr Opin Mol Ther 11 5 485 492 2009 19806496
  121. [123]Affronti ML Heery CR Herndon JE 2nd Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy Cancer 115 15 3501 3511 2009 19514083

Cited by

Sorted by citations

Authors
Chaichana, K. L., Pinheiro, L., & Brem, H.
Affiliations
Johns Hopkins University (US)
ORCID
Venue
Therapeutic Delivery
Publisher
Informa UK Limited
Published
2015-04
Volume
6
Issue
3
Pages
353-369
ISSN
  • 2041-5990 (ISSN-L)
  • 2041-6008
DOI
10.4155/tde.14.114
PMC
PMC4696051
OpenAlex
W2091857781
Cited by
91
References
1
Citations by year
2026: 6 · 2025: 10 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 10 · 2020: 10 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 2
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Delivery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA006973)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
high-grade glioma, glioblastoma, anaplastic astrocytoma, local drug delivery, convection-enhanced delivery, local gene therapy, tumor recurrence, brain tumor therapy
MeSH terms
Blood-Brain Barrier, Brain Neoplasms, Glioma, Humans, Polymers, Genetic Therapy, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review